Citigroup Analysts Give Bayer (BAYN) a €100.00 Price Target

Share on StockTwits

Citigroup set a €100.00 ($116.28) target price on Bayer (FRA:BAYN) in a report issued on Thursday, September 20th. The firm currently has a buy rating on the healthcare company’s stock.

Several other analysts have also recently issued reports on BAYN. UBS Group set a €130.00 ($151.16) target price on Bayer and gave the company a buy rating in a research report on Friday, August 17th. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, August 22nd. Sanford C. Bernstein set a €115.00 ($133.72) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, September 5th. Independent Research set a €105.00 ($122.09) price objective on Bayer and gave the stock a neutral rating in a research report on Monday, June 4th. Finally, Warburg Research set a €118.00 ($137.21) price objective on Bayer and gave the stock a neutral rating in a research report on Monday, June 4th. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of €98.80 ($114.88).

FRA:BAYN traded down €1.22 ($1.42) during midday trading on Thursday, hitting €76.10 ($88.49). The stock had a trading volume of 3,924,996 shares. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: Return on Equity (ROE)

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply